DGX vs BIO vs TMO vs DHR

For growth investors, Quest Diagnostics Incorporated (DGX) is the stronger pick with 11.

8% revenue growth year-over-year, versus 0. 7% for Bio-Rad Laboratories, Inc. (BIO). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 9. 2x trailing P/E (25. 0x forward), making it the more compelling value choice. Analysts rate Bio-Rad Laboratories, Inc. (BIO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bio-Rad Laboratories, Inc.

(BIO) is the cheapest at 9. 2x versus Danaher Corporation at 34. 9x. On forward P/E, Quest Diagnostics Incorporated is actually cheaper at 17. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Thermo Fisher Scientific Inc. wins at 9. 05x versus Danaher Corporation's 34. 35x.

Over the past 5 years, Quest Diagnostics Incorporated (DGX) delivered a total return of +47.

7%, compared to -57. 7% for Bio-Rad Laboratories, Inc. (BIO). Over 10 years, the gap is even starker: TMO returned +229. 1% versus BIO's +81. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Quest Diagnostics Incorporated (DGX) is the lower-risk stock at 0.

07β versus Thermo Fisher Scientific Inc. 's 1. 10β — meaning TMO is approximately 1393% more volatile than DGX relative to the S&P 500. On balance sheet safety, Bio-Rad Laboratories, Inc. (BIO) carries a lower debt/equity ratio of 21% versus 95% for Quest Diagnostics Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Quest Diagnostics Incorporated (DGX) is pulling ahead at 11.

8% versus 0. 7% for Bio-Rad Laboratories, Inc. (BIO). On earnings-per-share growth, the picture is similar: Bio-Rad Laboratories, Inc. grew EPS 142. 6% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, DGX leads at 3. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus 9. 0% for Quest Diagnostics Incorporated — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DHR leads at 20. 9% versus 10. 5% for BIO. At the gross margin level — before operating expenses — DHR leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Thermo Fisher Scientific Inc. (TMO) is the more undervalued stock at a PEG of 9. 05x versus Danaher Corporation's 34. 35x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Quest Diagnostics Incorporated (DGX) trades at 17. 8x forward P/E versus 25. 0x for Bio-Rad Laboratories, Inc. — 7. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 40. 6% to $247. 00.

In this comparison, DGX (1.

6% yield), DHR (0. 7% yield), TMO (0. 4% yield) pay a dividend. BIO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Quest Diagnostics Incorporated (DGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

07), 1. 6% yield, +181. 3% 10Y return). Both have compounded well over 10 years (DGX: +181. 3%, TMO: +229. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DGX is a mid-cap quality compounder stock; BIO is a small-cap deep-value stock; TMO is a mid-cap quality compounder stock; DHR is a mid-cap quality compounder stock. DGX, DHR pay a dividend while BIO, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.